AlncRNA HULC as an effective biomarker for surveillance of the outcome of cancer: A meta-analysis Xiaoliang Chen Jinbo Lin Yi Liu Ji Peng Yong Cao Zhan Su Tieqiang Wang Jinquan Cheng Dongsheng Hu 10.1371/journal.pone.0171210 https://plos.figshare.com/articles/dataset/AlncRNA_HULC_as_an_effective_biomarker_for_surveillance_of_the_outcome_of_cancer_A_meta-analysis/4610029 <div><p>Purpose</p><p>High expression of highly upregulated in iver cancer (HULC) has been found associated with increased metastasis and poor prognosis with cancer. This meta-analysis aimed to determine the pooled effect of HULC on metastasis and prognosis of cancers.</p><p>Method</p><p>The studies were accessed using multiple databases. RevMan5.3 and STATA14.0 were used to estimate pooled effects, the heterogeneity among studies, and publication bias for the association of HULC and overall survival (OS).</p><p>Results</p><p>A total of 9 studies of 966 cancer patients were included. Risk of lymph node metastasis was increased with high versus low HULC expression (pooled odds ratio [OR] = 4.83, 95% confidence interval [CI] 1.59–14.63) as was distant metastasis (pooled OR = 5.44, 95% CI 2.33–12.74). Furthermore, OS time was shortened with high HULC expression (pooled hazard ratio [HR] = 1.48, 95% CI 1.03–2.12), especially in Chinese patients (pooled HR = 2.04, 95% CI 1.55–2.68), and risk of recurrence was increased (pooled OR = 6.68, 95% CI 2.77–16.13).</p><p>Conclusion</p><p>HULC might be a potential biomarker for therapy and prognosis surveillance in cancers.</p></div> 2017-02-01 17:30:02 HR 966 cancer patients CI prognosis lymph node metastasis HULC expression STATA OS meta-analysis Purpose High expression